Walter Armstrong

Novartis CEO Daniel Vasella has built the Swiss firm into the fastest growing pharma in the world, and in the process gained a reputation as an outspoken visionary. But is he really as good as all that?

With the biotech industry reeling from the recession, big drugmakers hold all the cards when it comes to making deals, but picking a winner is still a gamble. Here are 10 to place stakes on.

The Belgian drugmaker is pursuing a sale, inking deals, issuing debt, and launching a power drug for Parkinson's—all at once.

Chris Viehbacher's first fast and furious six months at the top of Sanofi-Aventis have heads spinning...and rolling.

Due to pharma's voluntary moratorium on doling out totefuls of freebies and all the lattes you can swallow, thousands of docs, researchers, and reporters had only their sleep-deprived selves to carry from data dump to data dump at this week?s American Society of Clinical Oncology (ASCO) annual confab in Orlando, Florida.

Just when you thought it was safe to go back into M&A, the mega merger returns. What's right about Pfizer-Wyeth, and what's scary.

For aiming to be a game-changer in cardiovascular disease, we recognize comeback kid Crestor as the year's No. 1. Plus three fine finalists.

We know what you're thinking: new president, rotten economy, patent cliff. Do you feel Evel? Well, do you?

Everything you wanted to know about the year's most important deals—and what to watch for in the future